Ever heard of mast cells? Well, you might want to start paying attention to them.

For decades, chronic urticaria patients got antihistamines, then maybe Xolair if they were lucky and the antihistamines didn’t work.

Now there’s a wave of programs aimed at the source of the problem rather than the downstream itch.

Celldex finished enrolling 1,939 patients in two Phase 3 trials for barzolvolimab, an anti-KIT antibody that depletes mast cells outright.

Cogent Biosciences has a PDUFA date of December 30 for bezuclastinib in systemic mastocytosis.

Septerna (I love this company) is heading into Phase 2 with an oral MRGPRX2 inhibitor.

Even Regeneron and Sanofi just got a CHMP nod for Dupixent in pediatric CSU.

Well, into this very crowded room walks Allegria Therapeutics, a Basel-based preclinical biotech, with €1.3 million in non-dilutive grant money.

The funding comes from the Eureka Eurostars program and goes to a consortium called MastCURe that Allegria is coordinating. The other two members are Cube Biotech, which brings a membrane protein structure platform called NativeMP, and Fraunhofer ITMP-IA, which provides human skin-derived mast cell models for validation.

The stated goal is first-in-class mast cell-directed therapies for chronic urticaria.

So why bother?

By the time Allegria gets a candidate into the clinic, Celldex will likely be on the market, right?.

The bet here is that mast cell biology has more than one door.

Barzolvolimab depletes mast cells by blocking KIT.

Bezuclastinib goes after a specific KIT mutation.

Septerna shuts down one of the receptors that triggers degranulation.

None of those approaches are the full answer. Mast cells are involved in dozens of diseases beyond CSU, including mastocytosis, prurigo, atopic dermatitis, and cold urticaria, and patients respond differently to each mechanism.

What Allegria is using Cube Biotech for is interesting.

NativeMP solves membrane proteins in their native lipid environment, which matters because mast cell receptors are notoriously hard to crystallize and notoriously hard to drug. If you can get atomic-resolution structures of mast cell-specific receptors that nobody else can see properly, you can find new targets the existing players are simply blind to.

That’s the play. Not racing barzolvolimab to market. Finding the targets the antibody and the small-molecule guys are missing.

€1.3 million doesn’t get you to an IND. It gets you to a credible target and a hypothesis worth pitching to a Series A.

Watch for that next.